Scenic Biotech is a developer of a genomics and immunotherapy technologies created to unlock genetic suppressors.
Scenic Biotech has raised €28M across 1 funding round from 7 investors, most recently a Series A round in Mar 2022. Based in Amsterdam, Netherlands; active in Healthtech. Data as of 7 Aug 2026.
Timing: overdue vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2022-03-10 | Series A | €28M |
| BioGeneration Ventures,BioMedPartners,EIR Ventures,Inkef Capital,Nordic Life Science,Oxford Science Enterprises+1 more |
| View deal → |
